Atea Pharmaceuticals secures credit facility of up to $200 million from Hercules Capital
- Atea Pharmaceuticals secured a credit facility of up to $200 million from Hercules Capital, receiving $65 million at closing.
- Additional funding includes up to $35 million tied to a clinical milestone and $70 million tied to regulatory, financing and commercial milestones.
- A further $30 million may be available at the borrower's request, subject to lenders' sole discretion.
- The facility matures in 60 months; its 48-month interest-only period can extend to 60 months upon achieving a specified commercial milestone.
- Existing cash, cash equivalents and investments, together with initial proceeds, are expected to fund planned operations into mid-2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872971) on November 09, 2026, and is solely responsible for the information contained therein.